A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

Open-Label study evaluating safety and efficacy of SM-020 Gel 1.0% in subjects with Seborrheic Keratoses and Non-Melanoma Skin Cancers (i.e. Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ). Subjects will be enrolled into 1 of 5 cohorts. Each cohort will enroll approximately 5-10 subjects with at least 1 eligible lesion to be treated. A maximum of 5 lesions may be enrolled per subject. Treatment for all subjects and all lesions will be twice daily for approximately 28 days. Post treatment, residual lesions may be excised per standard of care for histological evaluation. The duration o

Trial Details

NCT ID
NCT06409195
Phase
PHASE2
Sponsor
DermBiont, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • SM-020 1% Gel
Locations (sample)
  • Charlotte, North Carolina, United States|35.22709,-80.84313

Key Eligibility Criteria

  • Subjects must meet all of the following criteria to be included in the study:
  • Must be able to comprehend and willing to sign an informed consent form (ICF).
  • Must complete a signed Health Information Portability and Accountability Act (HIPAA) authorization form which permits the use and disclosure of the…
  • Must be at least 18 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →